Evidence map›Paper›PMID 33066317›Full record

ArticleJournal of personalized medicine2020

Predictive Role of Biopsy Based Biomarkers for Radiotherapy Treatment in Rectal Cancer.

Yugang Wen, Senlin Zhao, Annica Holmqvist, Victoria Hahn-Stromberg, Gunnar Adell, Birgitta Holmlund, Surajit Pathak, Zhihai Peng, Xiao-Feng Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. The Role of WRAP53 in Cell Homeostasis and Carcinogenesis Onset.Current issues in molecular biology · 2022
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yugang WenDepartment of General Surgery, Shanghai General, School of Medicine, Shanghai Jiaotong University, Shanghai 200080, China.
Senlin ZhaoDepartment of General Surgery, Shanghai General, School of Medicine, Shanghai Jiaotong University, Shanghai 200080, China.
Annica HolmqvistDepartment of Oncology and Department of Biomedical and Clinical Sciences, Linköping University, SE-581 83 Linköping, Sweden.
Victoria Hahn-StrombergDepartment of Medical Cell Biology, Uppsala University, SE-751 05 Uppsala, Sweden.
Gunnar AdellDepartment of Oncology and Department of Biomedical and Clinical Sciences, Linköping University, SE-581 83 Linköping, Sweden.
Birgitta HolmlundDepartment of Oncology and Department of Biomedical and Clinical Sciences, Linköping University, SE-581 83 Linköping, Sweden.
Surajit PathakFaculty of Allied Health Sciences, Chettinad Academy of Research and Education, Kelambakkam, Chennai 603 103, India.
Zhihai PengDepartment of General Surgery, Shanghai General, School of Medicine, Shanghai Jiaotong University, Shanghai 200080, China.
Xiao-Feng SunDepartment of Oncology and Department of Biomedical and Clinical Sciences, Linköping University, SE-581 83 Linköping, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeRadiation therapy has long been contemplated as an important mode in the treatment of rectal cancer. However, there are few ideal tools available for clinicians to make a radiotherapy decision at the time of diagnosis for rectal cancer. The purpose of this study was to assess whether biomarkers expressed in the biopsy could help to choose the suitable therapy and provide predictive and/or prognostic information. EXPERIMENTAL

designIn total, 30 biomarkers were analyzed in 219 biopsy samples before treatment to discover the possibility of using them as an indicator for radiotherapy selection, diagnosis, survival and recurrence.

resultsTwenty-two biomarkers (COX2-RT, COX2-NonRT, etc.; 36.67%) had diagnostic value. For survival, four biomarkers (NFKBP65, p130, PINCH and PPAR) were significant in regulating gene promoter activity and overall survival, while four had a trend (AEG1, LOX, SATB1 and SIRT6). Three biomarkers (COX2, PINCH and WRAP53) correlated with disease-free survival, while eight had a trend (AEG1, COX2, Ki67, LOX, NFKBP65, PPAR and SATB1). Four biomarkers (COX2-RT, NFKBP65cyto-RT, P130cyto-NonRT and PPARcyto-RT) were independent prognostic factors for recurrence. NFKBP65 and SIRT6 were significantly correlated with lymph node metastasis regardless of radiation. Patients with high AEG1, LOX, NFKBP65, PPAR and SATB1 had or showed a positive trend for better survival after radiotherapy, while those with positive PINCH and WRAP53 expression would not benefit from radiotherapy.

conclusionsAEG1, LOX, NFKBP65cyto, PPAR and SATB1 could be used as indicators for choosing radiotherapy. COX2-RT, COX2-NonRT and some other biomarkers may provide additional help for diagnosis.

Indexed as

biomarkerbiopsyprognosisradiotherapyrectal cancer

Identifiers

PMID33066317
PMCPMC7712120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.